Hematological disease
Conditions
Interventions
co-infusion group:mobilized peripheral blood stem cells and low count of unrelated umbilical cord blood stem cells co-infusion
alone infusion group:mobilized peripheral blood stem cells alone
Sponsors
Tianjin First Center Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. The patient or his/her legal guardians must sign a consent form; 2. The patients therapeutic regimen is approved by the hospital ethics committee; 3. Aged 18-55, males and females; 4. Hematopoietic diseases: acute myeloid leukemia, acute lymphoblastic leukemia, Chronic leukemia, severe aplastic anemia, myelodysplastic syndrome, have transplant indication; 5. No completely HLA-identical donors; 6. No sever function diseases in heart, brain, lung, liver or kidney or other organs; 7. Acute leukemia achieve complete remission before transplantation and without CNS or extramedullary infiltration; 8. Karnofsky score is more than 60%, Eastern Cooperative Oncology Group (ECOG) physical status score 0-2; 9. Volunteers can be followed up for the treatment effect after transplantation.
Exclusion criteria
Exclusion criteria: 1. pregnant or lactating women; 2. severe organ dysfunction or disease, such as heart, liver, kidney and pancreas and other severe diseases and dysfunction; 3. Not suitable for Haplo-HSCT; 4. uncontrolled active infection within 4 weeks; 5. other cancers; 6. have taken part in other clinical tests within 6 weeks; 7. have a history of central nervous system disease; 8. addicted to some drugs; 9. the central nervous system and other organs were treated with maximum tolerated radiotherapy within 6 months; 10. the researchers think it is not suitable for the test; 11. The donor does not meet the requirements: HIV positive, active hepatitis B or C, bone marrow disease, onset of mental illness, poison, drug addiction, refused to donate peripheral blood, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| donor engraftment time;incidence and severity of graft-versus-host disease(GVHD),;recurrence rate of primary disease;DFS;OS;Treg;CD4+Th1;CD4+Th2;Thl7;DC; | — |
Countries
China
Contacts
Public ContactZhao Mingfeng
Department of Hematology, Tianjin First Center Hospital
Outcome results
None listed